Loading...

Financial Summary


Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

Healthcare
Buy
A-
Market Info
Financial Info
Financial Modelling
Symbol APVO
Price 0.636$
Beta 2.51
Volume Avrg. 0.37M
Market Cap 0.03B
Shares (2018) 22,500.05K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -176.57% Strong Sell
ROA -147.98% Strong Sell
Operating Margin -223.98% Strong Sell
Debt / Equity 63.40% Buy
P/E - Neutral
P/B 0.95 Buy

Income Statement

Download APVO income statement Download APVO income statement
Year 2013 2014 2015 2016 2017 2018
Earnings Per Share Basic ---2.93-5.550.33-2.39
Net Profit Margin -313.75-1.12-1.77-3.090.48-2.33
Earnings Per Share Diluted ---2.93-5.550.33-2.39
Revenue 0.1745.6333.6036.4314.6623.07
Weighted Average Shares Outstanding --20.2120.2421.3422.50
Gross Profit 0.1729.3816.6712.259.6511.85
Weighted Average Shares Outstanding (Diluted) --20.2320.2421.3422.50
Sales, General and Administrative Expense 15.4534.2843.0477.3369.1556.27
Dividend per Share ------
Operating Income -53.34-51.71-61.10-126.94-53.95-51.66
Gross Margin 1.000.640.500.340.660.51
Earnings before Tax -53.34-51.71-61.34-127.75-16.33-53.69
EBITDA Margin -309.83-1.09-1.74-3.39-3.47-2.14
Net Income -53.34-51.12-59.32-112.426.97-53.69
EBIT Margin -313.75-1.13-1.83-3.48-3.68-2.24
Net Income - Discounted ops ------
Profit Margin -313.75-1.12-1.76-3.090.48-2.33
Preferred Dividends ------
Free Cash Flow margin -0.00-0.00-0.00-0.00-0.00-0.00
R&D Expenses 38.0746.5934.7329.5229.0235.38
Interest Expense ----15.34-23.30-
Earnings Before Tax Margin -313.75-1.13-1.83-3.51-1.11-2.33
Consolidated Income -53.34-51.12-59.32-112.426.97-53.69
EBIT -53.34-51.71-61.34-126.94-53.95-51.66
EBITDA -52.67-49.69-58.43-123.58-50.82-49.27
Income Tax Expense --0.60-2.02-15.34-23.30-
Operating Expenses 53.5181.0977.77106.8598.1791.65
Cost of Revenue -16.2516.9324.185.0111.21
Net Income Com -53.34-51.12-59.32-112.426.97-53.69
Net Income - Non-Controlling int ------

Balance Sheet Statement

Download APVO income statement Download APVO income statement
Year 2014 2015 2016 2017 2018
Total current liabilities 19.8419.9419.5418.5117.61
Other Liabilities 8.369.86---
Long-term debt --18.3815.7319.28
Cash and cash equivalents 3.594.649.687.0930.64
Total debt --18.3819.0620.07
Cash and short-term investments 3.594.649.687.0930.74
Deferred revenue 4.547.160.81--
Inventories 17.6320.326.641.031.78
Tax Liabilities 1.8715.82---
Goodwill and Intangible Assets 25.1246.65-6.085.25
Deposit Liabilities -----
Tax assets 1.311.38---
Total non-current liabilities 5.5319.2121.7516.4619.48
Total current assets 41.5535.1371.4195.0848.69
Total liabilities 25.3639.1541.2934.9737.09
Payables 11.4710.0811.497.3511.67
Other comprehensive income --131.27155.84157.79
Short-term investments ---78.110.10
Retained earnings (deficit) -172.67-231.99-80.69-73.72-127.41
Property, Plant & Equipment Net 3.204.185.915.845.20
Total non-current assets 78.4292.6320.4421.9218.80
Other Assets 6.513.72---
Net Debt -3.59-4.648.7111.97-10.56
Investments ---78.110.10
Total shareholders equity 94.6188.6250.5782.0330.41
Total assets 119.97127.7791.86117.0167.49
Long-term investments -----
Receivables 13.826.464.282.145.22
Short-term debt ---3.330.80

Cash Flow Statement

Download APVO income statement Download APVO income statement
Year 2013 2014 2015 2016 2017 2018
Insurance (repayment) of debt ------
Net Cash/Marketcap 0.000.000.00---
Insurance (buybacks) of shares ------
Depreciation & Amortization 0.672.022.913.363.132.39
Dividend payments ------
Operating Cash Flow -51.39-47.01-48.76-36.86-41.57-51.42
Acquisitions and disposals --47.81----
Free Cash Flow -52.41-48.00-50.29-39.37-42.98-52.40
Net cash flow / Change in cash -3.591.045.04-2.5820.59
Effect of forex changes on cash ------
Financing Cash Flow 52.4199.4051.3389.309.53-0.79
Investment purchases and sales ------
Capital Expenditure -1.02-0.99-1.532.511.400.98
Stock-based compensation 0.951.071.113.814.882.14
Investing Cash Flow ------

Retained Earning Schedule

Year 2014 2015 2016 2017 2018
Retained Earnings (Previous Year) --173-232-81-74
Net Income -51-59-1127-54
Stock Dividends -122-264--
Divident Paid -----
Retained Earnings -173-232-81-74-127

PPE Schedule

Year 2014 2015 2016 2017 2018
Year 20142015201620172018
Gross PPE -3466
Annual Depreciation 43-1-1-2
Capital Expenditure -1-2311
Net PPE 34665

Intangible and Goodwill Schedule

Year 2014 2015 2016 2017 2018
Intangible and Goodwill (Previous Year) -2547-6
New Purchases -----
Intangible and Goodwill 2547-65
Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

0.636
-0.024 (-3.64%)

About


Marvin L. White
Healthcare
Biotechnology
Nasdaq Global Select

Aptevo Therapeutics Inc is a biosciences company. The Company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.